Key Points Novo Nordisk is in the middle of an important product launch, as it rolls out a pill version of its GLP-1 drug. The company hopes to regain lost market share in the still-emerging GLP-1 weight-loss space from its key rival, Eli Lilly. There are things to like about Novo Nordisk's opportunity with pills, but a name change isn't likely to do much for the business. 10 stocks we like better than Novo Nordisk › In some ways, Novo Nordisk (NYSE: NVO) clearly has an image problem. It effectively created the GLP-1 weight-loss drug market when it launched Wegovy. But it quickly lost the lead in this emerging niche to competitor Eli Lilly (NYSE: LLY) . Now, Novo Nordisk has a chance to make a comeback as it launches a pill version of its GLP-1 drug.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.